TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01125969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Description: Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Description: Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
Study: NCT02168738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-C labeled AceDoPC-DHA
Description: Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 13-C labeled AceDoPC-DHA
Description: Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 13-C labeled AceDoPC-DHA
Description: Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months
Study: NCT04195789

Intervention type: OTHER
Intervention: Lung sonography
Description: Realization of a lung sonography with scoring of the number of B-lines exploring 14 intercostal spaces.~Duration of the exam : twenty minutes. Recording for a second analysis by another lung specialist.
Study: NCT00777049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Hard gelatine capsule - 5mg and 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Hard gelatine capsule - 5mg and 20mg
Study: NCT02168738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-C labeled TG-DHA
Description: Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 13-C labeled TG-DHA
Description: Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 13-C labeled TG-DHA
Description: Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-C labeled PC-DHA
Description: Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 13-C labeled PC-DHA
Description: Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 13-C labeled PC-DHA
Description: Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months
Study: NCT00428220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: sunitinib
Study: NCT01563289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 times a day
Study: NCT00167180

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Donor Lymphocyte Infusion
Description: donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Donor Lymphocyte Infusion
Description: donor cells infused over 2 hrs at cell dose of 0.5 dx 10\^8 CD3+T-cells/kg
Study: NCT03610867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furaprevir capsule (SAD)
Description: There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furaprevir capsule (MAD)
Description: There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
Study: NCT00167180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Chemotherapy
Description: Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
Study: NCT01289223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Physicians Choice
Description: Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
Study: NCT02855723

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery: GS strategy
Description: sentinel node biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: Surgery: Classic strategy
Description: systematic lymphadenectomy
Study: NCT00871546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
Study: NCT02716103

Intervention type: OTHER
Intervention: blood collection

Intervention type: OTHER
Intervention: blood collection

Intervention type: OTHER
Intervention: bone marrow collection

Intervention type: OTHER
Intervention: bone marrow collection
Study: NCT03447756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: Capsules of either 2mg, 10mg, or 50mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo to match
Study: NCT03442907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24 hour blood pressure measurement, fluids, vasopressors
Description: Targeting individual blood blood pressure values during surgical procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Treatment according to Standard of care at the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf
Study: NCT02252198

Intervention type: OTHER
Intervention: Epistem Genedrive® and MolBio Truenat™
Description: S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2\*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
Study: NCT00616655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eszopiclone
Description: SEP-225441 (eszopiclone) total daily dose of 1.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eszopiclone
Description: SEP-225441 (eszopiclone) total daily dose of 0.9 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo total daily dose 0.9 mg
Study: NCT00867425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Lifestyle Management
Description: The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity).
Study: NCT01079091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADVOS (Hepa Wash)
Description: Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard of care treatment
Study: NCT01863225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
Study: NCT00943969

Intervention type: PROCEDURE
Group type: OTHER
Intervention: gastric bypass
Description: gastric bypass combines restrictive and malabsorptive procedures
Study: NCT01049516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy - Massed
Description: 10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
Study: NCT03336528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degludec
Description: Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner blood glucose (BG) between 100 mg/dL and 180 mg/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dL and 180 mg/dL.
Study: NCT00871546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 727965
Description: SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
Study: NCT01410292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GI and fiber meals
Description: meals with different fiber content and glycemic index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GI and fiber meals
Description: meals with different fiber content and glycemic index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GI and fiber meals
Description: meals with different fiber content and glycemic index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GI and fiber meals
Description: meals with different fiber content and glycemic index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals
Description: four different meal regarding GI and fiber content
Study: NCT01049516

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy - Spaced
Description: 10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Minimal Contact Control
Description: Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
Study: NCT03336528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart
Description: Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
Study: NCT01410292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals
Description: four different meal regarding GI and fiber content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals
Description: four different meal regarding GI and fiber content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meals
Description: four different meal regarding GI and fiber content
Study: NCT04654871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chondroitin Sulfate
Description: Glucosamine 500 mg Chondroitin sulfate sodium 400mg 3/day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~Supervised exercise thrice a week and Home Exercise 4 times a week Leg press knee extension Knee flexion Terminal knee extension Mini squats 3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy / Joint Mobilization
Description: Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy / Joint Mobilization
Description: Ant. tib-fem glide Post tib-fem glide thrice a week Pattelo-femoral joint mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: THE therapy
Description: Interferential and Heating for 20 min

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: THE therapy
Description: Interferential and Heating for 20 min
Study: NCT04370990

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic
Description: O2matic is a closed-loop-system that controls oxygenadministration according to SpO2. The aim is to maintain SpO2 within a predefined target interval, E.G. 88-92% with the lowest possible supplementation of oxygen by nasal cannula
Study: NCT00866346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR1-primed lymphocyte (PR1-CTL) Infusion
Description: Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg.
Study: NCT03889236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet Prolon
Description: 5-day fasting mimicking diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement Endocalyx
Description: Food supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00047333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03880448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 500mg/8h/7days
Study: NCT03336528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart
Description: Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
Study: NCT03880448

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cornstarch 500mg/8h/7days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal surgery
Description: periodontal surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: periodontal surgery
Description: periodontal surgery
Study: NCT00979368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-816336
Description: Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-816336
Description: Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-816336
Description: Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-816336
Description: Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-816336
Description: Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Suspension, Oral, 0 mg, Once on Day 1 only, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Suspension, Oral, 0 mg, Once on Day 1 only, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Suspension, Oral, 0 mg, Once on Day 1 only, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Suspension, Oral, 0 mg, Once on Day 1 only, 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
Study: NCT01129882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole IM depot - 300 mg or 400 mg
Study: NCT02980094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Antioxidant group(A)
Description: There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Oil group(O)
Description: There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Antioxidant and oil(AO)
Description: There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Milk Control group(C)
Description: There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)